Association between tacrolimus pharmacokinetics and cytochrome P450 3A5 and multidrug resistance protein 1 exon 21 polymorphisms

M Soda, M Fujitani, R Michiuchi, A Shibayama… - Transplantation …, 2017 - Elsevier
Background Individual differences in the pharmacokinetics (PK) of tacrolimus (TAC), an
immunosuppressive drug, are reportedly associated with single-nucleotide polymorphisms …

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

X Zhang, Z Liu, J Zheng, Z Chen, Z Tang… - Clinical …, 2005 - Wiley Online Library
Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and
wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P …

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

JN Roy, A Barama, C Poirier, B Vinet… - Pharmacogenetics and …, 2006 - journals.lww.com
Objective The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due
to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 …

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

N Tsuchiya, S Satoh, H Tada, Z Li, C Ohyama… - …, 2004 - journals.lww.com
Background. A body-weight-based dose of tacrolimus often results in marked individual
diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) …

Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation

S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre

Y Cheng, H Li, Y Meng, H Liu, L Yang… - … Journal of Clinical …, 2015 - Wiley Online Library
Aim As a substrate of cytochrome P450 (CYP) 3A5, tacrolimus is characterised by a narrow
therapeutic index and large inter‐individual variability. Our objective was to determine the …

Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12

E Thervet, D Anglicheau, B King, MH Schlageter… - …, 2003 - journals.lww.com
Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …

[HTML][HTML] Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients

YY Htun, NN Than, HK Swe - Korean Journal of …, 2020 - synapse.koreamed.org
Background Renal transplant is an effective treatment option for end-stage kidney disease
and tacrolimus is one of the most commonly used immunosuppressant drugs in renal …

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients

G Rong, L Jing, L Deng-Qing, Z Hong-Shan… - Transplantation …, 2010 - Elsevier
The aims of this study were to investigate the influence of CYP3A5 and MDR1 genetic
polymorphisms on tacrolimus pharmacokinetics in Chinese renal transplant recipients, so as …

Polymorphisms in CYP3A5* 3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.

P Wu, X Ni, M Wang, X Xu, G Luo… - Annals of transplantation, 2011 - europepmc.org
Background The purpose of this study was to investigate the effects of polymorphisms in
CYP3A5* 3, CYP3AP1, and MDR1, and of haplotype, on plasma levels of tacrolimus in …